GlassScriptPhysician profile
Jared Charles Abel
NPI 1023529401
$1,871.36
in general payments reported to CMS, 2019-2025
12 companies · $488 in 2025
The $488 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $422 · 2022: $382 · 2023: $309 · 2024: $271 · 2025: $488.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,068.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,067.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $371.10 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $290.88 | 2021-2024 | Farxiga, Lokelma |
| Abbott Laboratories | $179.75 | 2021-2025 | Epic |
| Abbvie INC. | $173.53 | 2021 | |
| Kyowa Kirin, INC. | $139.99 | 2025 | |
| Novo Nordisk INC | $135.50 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $125.01 | 2023 | |
| Axsome Therapeutics, INC. | $125.00 | 2025 | Auvelity |
| Sanofi-Aventis U.S. LLC | $101.45 | 2022 | |
| Lundbeck LLC | $79.06 | 2024 | Vyepti |
| E.R. Squibb & Sons, L.L.C. | $77.70 | 2023 | Camzyos |
| Amgen INC. | $72.39 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jared Abel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.